Sermorelin
Sermorelin is a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH) used to assess and stimulate natural growth hormone secretion. It is researched for cardiac repair, bone density, sleep regulation, epilepsy, and age-related GH decline.
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. It retains full biological activity for stimulating growth hormone (GH) release from the pituitary gland and is clinically used (as Geref) to assess GH secretory capacity, with broad research applications in cardiac repair, bone density, sleep regulation, and age-related GH insufficiency.
Overview
Sermorelin is one of several GHRH analogues developed to preserve the positive effects of natural GHRH while avoiding undesirable effects associated with direct GH administration. It stimulates endogenous GH production through the physiological GHRH axis, maintaining normal feedback regulation. Beyond its primary use in diagnosing and treating GH deficiency, sermorelin is of interest for reducing cardiac scarring after myocardial infarction, increasing bone density, improving nutrition in chronic illness, enhancing renal function, fighting dementia, and reducing seizure activity.
Mechanism of Action
Sermorelin binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. Unlike exogenous GH administration, sermorelin works through the physiological hypothalamic-pituitary axis, preserving normal negative feedback mechanisms mediated by GH and IGF-1. This means that GH levels rise in a regulated manner and cannot easily reach supraphysiological concentrations.
Sermorelin also activates GABA receptors in the central nervous system, which may explain its anticonvulsant properties. Additionally, it influences orexin secretion, linking GH axis activity to sleep-wake cycle regulation.
A notable pharmacological property is that sermorelin upregulates GHRH receptor expression rather than causing receptor downregulation, which prevents tachyphylaxis (tolerance) and eliminates the need for dose escalation over time.
Reconstitution Calculator
Sermorelin
Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue consisting of t
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Rapid Degradation and Analog Development
The DPP-IV-mediated cleavage of GRF 1-29 occurs within minutes of injection, generating the inactive fragment GRF(3-29). This rapid inactivation reduces the effective GH pulse amplitude and necessitates multiple daily injections for therapeutic effect. Mapping of the DPP-IV cleavage site at Ala²-Asp³ directly informed the D-Ala² substitution used in Mod GRF 1-29 (CJC-1295 no DAC), which blocks this cleavage and extends the half-life approximately 3-fold.
Age-Related GH Decline
Sermorelin has been studied as a treatment for age-related decline in GH secretion (somatopause). In elderly subjects, sermorelin stimulates GH release and increases IGF-1 levels, though the response is blunted compared to younger individuals due to age-related loss of somatotroph mass and increased somatostatin tone. This blunted response in aging populations further motivated development of the more potent modified analogs.
Sleep and Circadian GH Release
GH secretion is strongly linked to slow-wave sleep, with the largest endogenous GH pulse occurring during the first period of deep sleep. Sermorelin administration at bedtime has been shown to augment this nocturnal GH pulse, potentially improving sleep-associated anabolic and restorative processes.
Diagnostic Applications
The Geref Diagnostic formulation was used as a provocative test of pituitary GH reserve, providing an alternative to the insulin tolerance test (ITT). In the GHRH stimulation test, sermorelin is administered intravenously and serum GH is measured at timed intervals. A robust GH response confirms intact somatotroph function, while a blunted response suggests pituitary-level GH deficiency. This diagnostic application remains clinically relevant even after the therapeutic product's market withdrawal.
FDA Approval and Clinical Use
Sermorelin was approved based on clinical trials demonstrating effective GH stimulation in children with growth hormone deficiency. The diagnostic formulation (Geref Diagnostic) was used as an alternative to insulin tolerance testing for assessing pituitary GH reserve. The therapeutic formulation stimulated linear growth in GH-deficient children through restored endogenous GH secretion (Prakash et al., 1999).
Heart Health
A 2015 study in a porcine model of ischemic cardiomyopathy demonstrated that GHRH agonist treatment (including sermorelin) reduced myocardial infarct scar mass significantly. The treatment reduced cardiomyocyte apoptosis, increased extracellular matrix component production for adequate healing, promoted angiogenesis to damaged tissue, and reduced inflammatory mediators. Clinically, these effects translated to improved diastolic function, reduced scar size, and increased capillary density. Bagno et al. (2015) — J. Am. Heart Assoc.
Additional research confirmed that targeting the GHRH receptor represents a novel therapeutic approach for heart failure following myocardial infarction. Kanashiro-Takeuchi et al. (2015) — Oncotarget
Epilepsy
GABA is a central nervous system inhibitory neurotransmitter that reduces electrical excitability. Many anti-seizure medications work by enhancing GABAergic signaling. Research has shown that GHRH analogues including sermorelin suppress seizures by activating GABA-A receptors, offering a potential new mechanism for seizure control with potentially fewer side effects than existing anticonvulsants. Tang et al. (2017) — Sci. Rep.
Sleep Regulation
An intact GHRH axis is necessary for proper orexin secretion and function, linking growth hormone physiology to sleep-wake cycle regulation. Research in animal models demonstrates that exogenous administration of sermorelin and other GHRH agonists can boost orexin secretion, suggesting therapeutic potential for sleep disorders. Shepherd et al. (2007) — Comp. Biochem. Physiol.
Advantages Over Exogenous Growth Hormone
Sermorelin is preferred over direct GH administration for several reasons. First, it is subject to physiological feedback mechanisms that prevent common GH-related problems including overdose, improper dosing, and side effects such as edema, joint pain, and physiological dysregulation. Walker (2006) — Clin. Interv. Aging
Second, sermorelin is not subject to significant tachyphylaxis. Rather than downregulating GHRH receptors, the body upregulates their production with continued sermorelin use. This ensures consistent effects without dose escalation requirements.
Safety Profile
Sermorelin has a well-established safety profile from decades of clinical use. Common side effects include injection site reactions (pain, redness, swelling), facial flushing, and transient headache. Because it works through physiological feedback mechanisms, the risk of GH excess is substantially lower than with direct GH administration. Sermorelin does not cause significant tachyphylaxis. Rare adverse effects include dizziness, hyperactivity, and somnolence. It is contraindicated in patients with active malignancy, as GH axis stimulation could theoretically promote tumor growth. Long-term studies have not identified significant safety concerns when used at therapeutic doses.
Pharmacokinetic Profile
Sermorelin — Pharmacokinetic Curve
Subcutaneous injectionOngoing & Future Research
- GHRH agonist MR-409 (sermorelin derivative) being investigated for cardiac repair post-MI (DOI: 10.1016/j.jacbts.2022.09.005).
- Research into cardioprotective GHRH agonists for chemotherapy-induced cardiomyopathy (PMID: 36610076).
- Investigation of GHRH agonists for sleep disorders, leveraging the orexin-GHRH axis connection.
- Exploration of sermorelin in age-related cognitive decline, based on IGF-1's known neuroprotective effects.
- Development of longer-acting GHRH analogues with improved pharmacokinetic profiles.
Quick Start
- Typical Dose
- 200-300mcg per dose (up to 500mcg for athletic performance)
- Frequency
- Once daily at bedtime (aligns with natural GH pulse)
- Route
- Subcutaneous injection
- Cycle Length
- 3-6 months continuous
- Storage
- Reconstituted: 2-8°C, use within 10-30 days
Molecular Structure
- Formula
- C149H246N44O42S
- Weight
- 3 Da
- Length
- 29 amino acids
- CAS
- 86168-78-7
- PubChem CID
- 86168
- Exact Mass
- 180.0357 Da
- LogP
- 0.9
- TPSA
- 67.3 Ų
- H-Bond Donors
- 1
- H-Bond Acceptors
- 3
- Rotatable Bonds
- 2
- Complexity
- 186
Identifiers (SMILES, InChI)
InChI=1S/C8H8N2OS/c11-6-5-8(10-6)12-7-3-1-2-4-9-7/h1-4,8H,5H2,(H,10,11)
JUGBCROTSIUESU-UHFFFAOYSA-NResearch Indications
Muscle Growth
1.26kg lean mass increase documented in elderly men with improved muscle strength tests.
Endogenous IGF-1 stimulation drives protein synthesis and muscle growth.
Enhanced recovery through physiological GH stimulation.
Anti-Aging
Doubles 12-hour GH release in elderly subjects over 6 weeks.
Decreased adiposity and improved lean mass distribution.
Improved skin thickness and quality.
Hormonal
Preserves natural axis function without suppression.
Maintains physiological GH release patterns.
Research Protocols
intravenous Injection
In the GHRH stimulation test, sermorelin is administered intravenously and serum GH is measured at timed intervals.
intranasal Injection
Intranasal spray is available with 69% patient preference over injection. Lower bioavailability but bypasses first-pass metabolism.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Nasal administration | 30+ mcg/kg | Once daily at bedtime | —(Route: Nasal spray) |
subcutaneous Injection
GHRH analog administered at bedtime to align with natural nocturnal GH secretion peaks.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Loading phase | 200 mcg | Once daily | Weeks 1-2(Administer at bedtime) |
| Escalation 1 | 300 mcg | Once daily | Weeks 3-4 |
| Escalation 2 | 400 mcg | Once daily | Weeks 5-6 |
| Full dose | 500 mcg | Once daily | Weeks 7-8+(Typical cycle: 3-6 months) |
Reconstitution Guide (5mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 1.67 mg/mL
- For 200 mcg dose: draw 12 units (0.12 mL)
- For 300 mcg dose: draw 18 units (0.18 mL)
- For 500 mcg dose: draw 30 units (0.30 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
Excellent combination producing 3-5 fold increases in GH release.
Highly effective combination - CJC-1295 provides sustained 6-8 day release while sermorelin offers immediate pulsatile effects.
Combined GHRH+GHRP-2 produces 54-fold GH increases compared to 20-fold with GHRH alone.
The most popular synergistic combination. Sermorelin acts on GHRH-R while ipamorelin acts on GHS-R1a — two distinct receptor pathways on pituitary somatotrophs producing amplified GH release. See Sermorelin + Ipamorelin Blend.
Sermorelin (GHRH pathway) + GHRP-2 (ghrelin pathway) for synergistic GH release. GHRP-2 is less selective than ipamorelin but may produce greater peak GH amplitudes. See Sermorelin + GHRP-2 Blend.
Similar GHRH + GHSR synergy. GHRP-6 is the least selective GHRP, also increasing appetite significantly. See Sermorelin + GHRP-6 Blend.
Triple combination for maximal GH release through both receptor systems. See Sermorelin + GHRP-6 + GHRP-2 Blend.
What to Expect
What to Expect
IGF-1 elevation begins; improved sleep quality and recovery
Body composition changes begin; increased energy and well-being
Visible muscle tone improvements; fat reduction; skin quality enhancement
Sustained improvements; optimal IGF-1 elevation
Maximum benefits: muscle growth, fat loss, anti-aging effects
Safety Profile
Common Side Effects
- Injection site reactions (16.7% of patients - generally mild)
- Nasal irritation (intranasal route)
Contraindications
- Active malignancy
- Pituitary tumors
- Pregnancy
Discontinue If
- Signs of pituitary tumor growth (headaches, vision changes)
- Severe injection site reactions or generalized allergic responses
- Uncontrolled diabetes or significant glucose intolerance
- New onset or worsening malignancy symptoms
Quality Indicators
What to look for
- Completely clear and colorless solution without particles, cloudiness, or precipitation
- Greater than 98% peptide purity per USP standards
- Sterile, nonpyrogenic lyophilized powder
- Maintained at 2-8°C throughout transport
- Produced in FDA-registered facilities following cGMP
Caution
- Brief room temperature exposure acceptable up to 72 hours but should be refrigerated promptly
Red flags
- Any cloudiness, particles, color changes, or precipitation indicates degradation
- Molecular weight should be exactly 3,358 daltons (free base) or 3,418 daltons (acetate salt)
Frequently Asked Questions
References (14)
- [1]FDA Approval Study - Geref International Study Group Trial (1996)
- [2]Adult Anti-Aging Study - Corpas et al. (1992)
- [3]Pharmacokinetic Profile (1996)
- [4]Body Composition in Elderly (1992)
- [5]Nasal Administration Study (1990)
- [12]Tornesello et al — Growth Hormone Secretagogues in the Treatment of Age-Related Conditions Int. J. Mol. Sci. (2022)
- [13]Stanley et al — GHRH Agonist MR-409 Promotes Recovery After Myocardial Infarction Through Cardiac Repair Mechanisms JACC Basic Transl. Sci. (2023)
- [14]Garcia-Fernandez et al — Neuroendocrine Aging: Growth Hormone-Releasing Hormone and Its Agonists as Therapeutic Agents Front. Endocrinol. (2022)
- [6]Bagno, L. L. et al Growth Hormone-Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy J. Am. Heart Assoc. (2015)
- [7]Kanashiro-Takeuchi, R. M. et al New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor Oncotarget (2015)
- [8]Tang, S. et al Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy Sci. Rep. (2017)
- [9]Shepherd, B. S. et al Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout Comp. Biochem. Physiol. A (2007)
- [10]Walker, R. F Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin. Interv. Aging (2006)
- [11]Mendoza et al — Growth Hormone-Releasing Hormone Agonists Protect Against Doxorubicin-Induced Cardiotoxicity Cardiovasc. Res. (2023)
Sermorelin / Ipamorelin Blend
A research peptide blend combining Sermorelin (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist), studied for synergistic amplification of growth hormone release with complementary cardiovascular, skeletal, and metabolic effects.
Setmelanotide (Imcivree)
Setmelanotide (Imcivree) is a highly selective MC4R agonist cyclic octapeptide FDA-approved in 2020 for the treatment of obesity caused by POMC, PCSK1, or LEPR deficiency. It restores melanocortin signaling downstream of genetic defects in the leptin-melanocortin pathway.